ESOCAP SELECTED AS A FINALIST TO PRESENT AT THE RESI INNOVATION CHALLENGE ON MARCH 23, 2020

Basel, Switzerland, March 3, 2020

EsoCap has been selected among 200+ companies as a finalist to present in the RESI Europe 2020 Innovation Challenge.

The RESI (Redefining Early Stage Investment) conference series was created to bring together startups in the biotech, medtech and digital health areas with early-stage investors. The goal is to maximize the capability of these companies, from seed to series B, to find partners who are a fit for their technology and stage of development. The RESI conference takes place annually in the USA, Europe and Asia.

"We are very excited to present at the RESI Europe 2020 conference in Paris", said Isabelle Racamier, EsoCap AG CEO. "This is a great validation of the innovative nature of our technology and business strategy." The EsoCap unique topical application technology may be beneficial in at least 6 indications affecting 370 million patients, including gastroenterology, oncology and orphan diseases. "The EsoCap smart application technology is a paradigm shift for the effective and safe treatment of esophageal diseases" said Dr. Peter Stangier, EsoCap AG Director Strategic Planning.

About EsoCap

EsoCap AG is a Swiss privately funded company based in Basel, Switzerland.

EsoCap's vision is to improve the lives of patients with serious diseases through the development of a unique topical drug delivery platform for diseases of the upper gastrointestinal tract.

Topical treatment in the upper gastrointestinal tract is extremely difficult to achieve due to ultra-short transit times, with less than two seconds from the mouth to the stomach.

EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for the local treatment of diseases of the upper gastrointestinal tract.

For more information, please visit www.esocap-biotech.com.

Contact:

Isabelle Racamier, CEO

isabelle.racamier@esocapbiotech.com

EsoCap AG
Malzgasse 9
4052 Basel
Switzerland